| Data Request ID | Lead Investigator | Institution | Research Proposal Title | Publication | Data Contributor(s) | Altmetrics Score | PubMed Citation Total |
|---|---|---|---|---|---|---|---|
| 4324 | Peng Xie | Institute of Neuroscience, Chongqing Medical University | Comparative efficacy and tolerability of new-generation antidepressants for major depressive disorder in children and adolescents: an individual patient data meta-analysis | Xiang, Yajie, Cuijpers, Pim, Li, Wei, Bao, Qingyan, Weisz, John R., Shi, Jie, Du, Xiaoyan, Yang, Hongmei, Barth, Jürgen, Coghill, David, Leucht, Stefan, Hazell, Philip, Cohen, David, Ravindran, Arun V., Michael, Kurt D., Teng, Teng, Zhou, Xinyu, Lu, Lin and Xie, Peng ""An Individual Participant Data Analysis: Optimizing Pharmacological Treatment in Children and Adolescents With Major Depressive Disorder"". Journal of the American Academy of Child & Adolescent Psychiatryvol. , no. , May. 2026, pp. doi:10.1001/jama.2026.1327 | Lilly, GlaxoSmithKline, Pfizer Inc. | 0 | |
| 4917 | Andrea Cipriani | University of Oxford | Choosing the Right Antidepressant for Depressive Disorder in Adults: Individual Patient Data Network Meta-Analysis | Cipriani, Andrea, Fernandes, Karen Barros Parron, Mulsant, Benoit H., Efthimiou, Orestis, Williams, Nicola, Mort, Sam, Elgarf, Rania, Liu, Qiang, Haque, Nyla, Potts, Jennifer, Ede, Roger, Fox, Robin, Liboni, Marcos, Nesi Cavicchioli, Diego A., Simon, Judit, Smith, Katharine A., Zangani, Caroline, Li, Zhenpeng, Taylor, Ursula, Husain, M. Ishrat, Cipriani, Maddalena, Carpaneze Dalaqua, Paulo V., Leite, Eduardo Fernandes, Aliano Gâmbaro, Gustavo, Nabhan Silveira, Diogo, Manfredin Vila, Luísa, Liboni Cavicchioli, Fernanda, Furukawa, Toshi A., Naci, Huseyin, Ostinelli, Edoardo G., null, null, Adinda, Arradea Triesty, Ahmed, Nadeem, Aronica, Rosario, Batista, Eduarda, Benjamin, Jithen, Binnian, Ian, Carson, Ruth, Collins, Helen, Cook, Johanna, Delahay, Rachel, De Crescenzo, Franco, Engonidou, Lazarina, Gilbody, Simon, Hong, James, Hughes, Owen, Jaquiery, Matt, Johnston, Benjamin, Lewis, Gemma, Paggi, Andrea, Rizzopesci, Nicola, Sealy, Pippa, Shah, Neetul, Shaw, Rachel, Singh, Ilina, Stevens, Katherine, Tanna, Jaimini, Tomlinson, Anneka, Wainwright, Laurence, Wooding, Nick, Yu, Ly-Mee, Kloiber, Stefan, Mueller, Daniel, Kim, Helena K., Jones, Brett D.M., Ortiz, Abigail, Blumberger, Daniel, Salanti, Georgia, Araújo, Stéphanie P., Bignardi, Paulo R., Camargo, Bruna G., Colado Simões, Andréa N., de Vasconcelos, João Pedro, Fernandes, Bianca B. P., Gobbi, Isadora L., Haber, Rafael S. A., Jacovetti, Renato C., Liboni, Augusto B. , Martins, Caio C. S., Oliveira, Amanda P., Ramos, Giulia G. A., Rodrigues, Carolina B. N., Santos, Raul H. M., Silva, Letícia F. R., Tassi, Gabriela G. and Tomazini, Vitor F. ""A Decision-Support System to Personalize Antidepressant Treatment in Major Depressive Disorder"". JAMAvol. 335, no. 14, Apr. 2026, pp. 1219 doi: 10.100110.1001/jama.2026.1327 | Lilly, GSK, Lundbeck | 1 | |
| 5921 | Paul Schulz | University of Texas Health Science Center Houston | The influence of bapineuzumab and semagacestat on rapid progressors: A retrospective cohort study | Harris, Kristofer, Shyer, Madison, Wang, Dulin, He, Elizabeth, Cattani, Matias, Zhang, Catherine, Farrell, Christine M., Jiang, Xiaoqian, Kim, Yejin and Schulz, Paul E. "The influence of bapineuzumab and semagacestat on rapid progressors: A retrospective cohort study"". The Journal of Prevention of Alzheimer's Diseasevol. 13, no. 3, Mar. 2026, pp. 100483 doi: 0.1016/j.tjpad.2026.100483 | Lilly | N/A | N/A |
| 6008 | David Hsieh | University of Texas Southwestern Medical Center | Patterns of outcomes and the relevance surrogate endpoints in patients treated with immune checkpoint inhibitors | Govindu, Saiabhiroop, Gowda, Prashanth, Muquith, Maishara, Espinoza, Magdalena and Hsiehchen, David "Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumab". Journal for ImmunoTherapy of Cancervol. 14, no. 1, Jan. 2026, pp. e013727 doi: /10.1136/jitc-2025-013727 | Roche | 3 | |
| 6739 | Rifaquat Rahman | Dana-Farber/Brigham and Women's Cancer Center (Dana-Farber Cancer Institute) | Evaluation of Differences in Trial and Non-Trial Patients and Leveraging of External Data for More Efficient Clinical Trial Designs in Newly Diagnosed Glioblastoma | Rudra Gupta, Tulika, Polley, Mei-Yin C., Redd, Robert, Lee, Eudocia Q., Arrillaga-Romany, Isabel, Gilbert, Mark R., Tan, Yujue, Touat, Mehdi, Drappatz, Jan, Welch, Mary R., Galanis, Evanthia, Ahluwalia, Manmeet S., Colman, Howard, Nabors, L. Burt, Hepel, Jaroslaw, Elinzano, Heinrich, Schiff, David, Chukwueke, Ugonma N., Beroukhim, Rameen, Nayak, Lakshmi, McFaline-Figueroa, J. Ricardo, Batchelor, Tracy T., Kaley, Thomas J., Lu-Emerson, Christine, Mellinghoff, Ingo K., Bi, Wenya Linda, Arnaout, Omar, Peruzzi, Pier Paolo, Haas-Kogan, Daphne, Tanguturi, Shyam, Aizer, Ayal, Doherty, Lisa, Santagata, Sandro, Meredith, David M., Chiocca, E. Antonio, Reardon, David A., Ligon, Keith L., Weller, Michael, Mehta, Minesh P., Wen, Patrick Y., Trippa, Lorenzo and Rahman, Rifaquat "Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data"". Journal of Clinical Oncologyvol. , no. , May. 2026, pp. doi:10.1200/JCO-25-01586 | Roche, Project Data Sphere | 0 | |
| 7074 | Gregory Lip | University of Liverpool | History of bleeding is associated with higher risk of cardiovascular outcomes in patients with atrial fibrillation: a report from the GLORIA-AF registry phase III | Corica, B, Romiti , G F, Proietti, M, Boriani, G, Olshansky, B, Chao , T F , Huisman, M V and Lip , G Y H "History of bleeding is associated with higher risk of cardiovascular outcomes in patients with atrial fibrillation: a report from the GLORIA-AF registry phase III". European Heart Journal 2025 doi:10.1093/eurheartj/ehaf784.735"a> | Boehringer Ingelheim | N/A | N/A |
| 7163 | Laura Mezquita | Hospital Clinic and the Translational Genomics Group at IDIBAPS | Prospective validation of the Lung Immune Prognostic Index in patients with non-small cell and small cell lung cancers. | Roulleaux-Dugage, Matthieu, Yurchenko, Andrey, Nikolaev, Sergey, Nabet, Barzin, Corgnac, Stéphanie, Anquetil, Céline, Srivastava, Minu K, Gayevskiy, Velimir, McNally, Virginia, Mezquita, Laura, Perfettini, Jean-Luc, Mouraud, Severine, Massard, Christophe, Besse, Benjamin, Loriot, Yohann, Marabelle, Aurelien, Chaput, Nathalie and Auclin, Edouard "VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC". Journal for ImmunoTherapy of Cancervol. 14, no. 6, Jun. 2026, pp. e014991 doi: 10.1136/jitc-2026-014991 | Roche | 0 | |
| 7384 | Ulrich Mansmann | Department for Medical Information Processing, Biometry, and Epidemiology; Ludwig-Maximilian’s University München | Application of Estimands and Causal Reasoning in the Reanalysis of Endpoint Measures in Advanced/Metastatic Non-Small Cell Lung Cancer Clinical Trials | Al Tawil, Amani, Lauseker, Michael and Mansmann, Ulrich "Estimating causal effects on quality of life under treatment discontinuation: the ALTA-1L trial"". Journal of Clinical Epidemiologyvol. 193, no. , May. 2026, pp. 112189 doi:10.1016/j.jclinepi.2026.112189" | Takeda | 0 | |
| 7404 | Reena Khanna | Lawson Health Research Institute | A Study to Assess the Correlation Between Harvey Bradshaw Index and Patient Reported Outcome 2 in Crohn's Disease Patients Enrolled in Large Scale Randomized Controlled Trials | Khanna, Reena, Son, Surim, Zou, Guangyong and Roshanov, Pavel S "Estimation of the Harvey Bradshaw Index from the Patient-Reported Outcome 2 in Crohn’s Disease: Results Based on a Large Scale Randomized Controlled Trial". Inflammatory Bowel Diseasesvol. 31, no. 8, Dec. 2024, pp. 2097-2105 doi: 10.1093/ibd/izae281 | Takeda | 6 | |
| 7595 | Ashley Hopkins | Flinders University | Predicting therapeutic outcomes to immune checkpoint inhibitors used in cancer treatment_012022 | Li, Lee X, Shahnam, Adel, Kichenadasse, Ganessan, Murray, Lewis, Woodman, Richard, Abuhelwa, Ahmad Y, Modi, Natansh D, Rowland, Andrew, Hopkins, Ashley M and Sorich, Michael J ""Heterogeneous Treatment Effect of Immune Checkpoint inhibitors by Pre-treatment Prognosis in Randomised Controlled Trials"". JNCI Cancer Spectrumvol. , no. , Jan. 2026, pp. doi: 0.1093/jncics/pkaf127 | Roche | 0 | 2 |
| 7599 | Hwanhee Hong | Duke University | Combining data sources to identify effect moderation for personalized mental health treatment | Wang, Qiao and Hong, Hwanhee "Bayesian Hierarchical Models With Calibrated Mixtures of g‐priors for Assessing Treatment Effect Moderation in Meta‐Analysis"". Statistics in Medicinevol. 45, no. 8-9, Apr. 2026, pp. doi:10.1002/sim.70510 | Johnson & Johnson, Lundbeck, Takeda | 0 | |
| 7599 | Hwanhee Hong | Duke University | Combining data sources to identify effect moderation for personalized mental health treatment | Lemoto, Elaona "Bayesian Hierarchical Models for the Combination of Data from Heterogeneous Sources". ProQuest LLC Duke University ProQuest Dissertations & Theses, 2026 Publication link | Johnson & Johnson, Lundbeck, Takeda | N/A | N/A |
| 7661 | Baocheng Chang | Chu Hsien-I Memorial Hospital, Tianjin Medical University | Effects of Lixisenatide on the primary prevention of diabetic kidney disease in population with high risk | Jiang, Wenhui, Wang, Jingyu, Li, Jing, Li, Yongmei, Zhang, Yi, Xu, Jie, Zhang, Jinghang, Gao, Zhongai, Cheng, Jingli, Yang, Juhong and Chang, Baocheng "Cardiorenal risk stratification in high-risk type 2 diabetes using a simple clinical score: findings from the ELIXA trial". Frontiers in Endocrinologyvol. 17, no. , Mar. 2026, pp. doi:10.3389/fendo.2026.1768816 | Sanofi | 0 | |
| 7667 | Ashley Hopkins | Flinders University | Summarising the therapeutic and adverse effects of anticancer medicines according to race and sex: pooled analysis of clinical trials of contemporary treatments for solid tumours | Chhetri, Rakchha, Modi, Natansh D, Menz, Bradley D, Cornelisse, Erik, Postma, David, Kuderer, Nicole M, Lyman, Gary H, Swain, Sandra M, Li, Lee X, Abuhelwa, Ahmad Y, McKinnon, Ross A, Vatandoust, Sina, Kichenadasse, Ganessan, Rowland, Andrew, Sorich, Michael J and Hopkins, Ashley M "Sex-based prognosis in industry-sponsored advanced solid tumor trials: an individual participant data meta-analysis of survival and adverse events". JNCI: Journal of the National Cancer Institutevol. , no. , Feb. 2026, pp. doi: 10.1093/jnci/djag046 | AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Inc., Lilly, Pfizer Inc., Roche, Sanofi, Takeda | 0 | |
| 7758 | Nahid Sultana | University of Sheffield | Indirect comparisons of time-to-event outcomes using single-arm studies in health technology assessment (Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma) | Sultana, Nahid "Indirect Comparisons with Population Adjustment Methods using Single-arm Studies in Health Technology Assessment". University of Sheffield UK, 2024 doi: 10.25934/PR00007758 | GSK | N/A | N/A |
| 7779 | Luís Inês | University of Beira Interior | Derivation and validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) severe disease activity category: post-hoc analysis of the anifrolumab clinical trials in active systemic lupus erythematosus. | Jesus, Diogo, Henriques, Carla, Matos, Ana, Doria, Andrea and Inês, Luís "S13:01 The novel SLE-DAS responder index aligns clinical endpoints with patient experience and outperforms BICLA and SRI-4 in capturing HRQoL: post-hoc analysis in the MUSE, TULIP-1 and TULIP-2 trials". Oral Presentationsvol., no., Mar. 2026, pp. A20-A20 doi: 10.1136/lupus-2026-el.17 | AstraZeneca | N/A | N/A |
| 7779 | Luís Inês | University of Beira Interior | Derivation and validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) severe disease activity category: post-hoc analysis of the anifrolumab clinical trials in active systemic lupus erythematosus. | Jesus, Diogo, Henriques, Carla, Matos, Ana, Doria, Andrea and Inês, Luís "PT7:02 Discordance between SLEDAI-2K and BILAG-2004 disease activity classification leads to divergent treatment decisions under EULAR 2023 recommendations: a post-hoc analysis of anifrolumab trials". Short Oral Presentationsvol., no., Mar. 2026, pp. A72.2-A73 doi: 10.1136/lupus-2026-el.72 | AstraZeneca | N/A | N/A |
| 7779 | Luís Inês | University of Beira Interior | Derivation and validation of the Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) severe disease activity category: post-hoc analysis of the anifrolumab clinical trials in active systemic lupus erythematosus. | Jesus, Diogo, Henriques, Carla, Matos, Ana, Doria, Andrea and Inês, Luís Sousa "SLE-DAS responder index: a novel outcome measure with high performance for physician and patient outcomes in anifrolumab phase 2–3 trials". Rheumatologyvol. 65, no. 5, Apr. 2026, pp. doi: 10.1093/rheumatology/keag177 | AstraZeneca | N/A | 0 |
| 7828 | Sofia Ramiro | Leiden University Medical Center | SPondyloarthritis: EARly Definition (ASAS-SPEAR): Analysis of Symptom Duration Thresholds Using Pooled Data from Randomized Controlled Trials | Benavent, D, Navarro-Compán, V, Capelusnik, D and Ramiro, S "Symptom duration and flare risk after biologic DMARD withdrawal in axial spondyloarthritis: a meta-analysis of randomized withdrawal trials". volume 85, supplement 1, pg. s2092, 2026 Publication link | AbbVie, Johnson & Johnson, Eli Lilly, Pfizer, UCB | N/A | N/A |
| 7842 | Marco Tagliamento | IRCCS Ospedale Policlinico San Martino | Pooled Efficacy and Safety Analysis of the Phase III Studies of Alectinib vs. Crizotinib in Untreated ALK-Positive Non-Small Cell Lung Cancer | Tagliamento, Marco, Bruzzone, Marco, Blondeaux, Eva, Dall’Olio, Filippo, Aldea, Mihaela, Genova, Carlo, Marinello, Arianna, Remon, Jordi, Hendriks, Lizza E.L., Del Mastro, Lucia, Planchard, David, Barlesi, Fabrice, Lambertini, Matteo and Besse, Benjamin "Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX". European Journal of Cancervol. 243, no., Jul. 2026, pp. 116867 doi: 10.1016/j.ejca.2026.116867 | Roche | 0 | |
| 7844 | Linong Ji | Peking University People's Hospital | Risk stratification and responder identification using a baseline model and a dynamic risk prediction model for GLP-1RA and SGLT2i in T2DM: a machine learning facilitated posthoc analysis of CVOTs | Huang, Qi, Zou, Xiantong, Boyko, Edward J, Lian, Zhouhui, Zhou, Xianghai, Han, Xueyao and Ji, Linong "Dynamic surveillance of the cardiovascular risk and identification of treatment responders in type 2 diabetes using a machine learning–based model"". European Journal of Preventive Cardiologyvol. , no. , Apr. 2026, pp. doi: 10.1093/eurjpc/zwag196 | GSK, BioLINCC, Johnson & Johnson | N/A | 0 |
| 7849 | Igor Stojkov | Paul-Ehrlich-Institut | Determinants of study design for vaccines against opportunistic bacterial infections: a proof-of-concept for data-driven, individual patient data (IPD) analyses. | Stojkov, Igor, Marchioro, Linda, Bekeredjian-Ding, Isabelle and Hofner, Benjamin "Pooled analyses of Clostridioides difficile vaccine trials identify baseline predictors for vaccine response". Scientific Reportsvol. 16, no. 1, Mar. 2026, pp. doi: 10.1038/s41598-026-42375-5 | Sanofi | 1 | |
| 7850 | Vipul Jairath | The University of Western Ontario | Impact of concomitant baseline medication, advanced age and racial differences on efficacy of biologics and small molecules for Inflammatory Bowel Disease | Ahuja, Dhruv, Choi, Jaeyoun, Zou, Guangyong, Goodwin, Shane W., Jairath, Vipul and Singh, Siddharth "Impact of Age on Efficacy and Safety of Advanced Therapies During Induction in Ulcerative Colitis: An Individual Patient Data Pooled Analysis from Randomized Controlled Trials". Digestive Diseases and Sciencesvol. , no. , Feb. 2026, pp. doi:10.1007/s10620-026-09753-5 | Takeda, Pfizer, AbbVie, Johnson & Johnson | N/A | 0 |
| 8053 | Alexander G Mathioudakis | Manchester University NHS Foundation Trust | ICS-RECODE: Predictors of treatment REsponse to inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease: randomised COntrolled trials individual participant Data re-Evaluation. | Mathioudakis, A G, Bate, S, Fortescue, R, Fullwood, C, Sperrin, M, Hurst, J R, Clarke, M, Quint, J K, Simmonds, M, Fally, M, Wang, R, Hansel, J, Miligkos, M, Manohar, S, Linnell, J, Preston, A, null, null, Woodcock, A, Stewart, L, Singh, D and Vestbo, J "C93-02 Blood Eosinophil Count Predicts Inhaled Corticosteroids Response in COPD: Results From the Ics-Recode Individual Participant Data Meta-Analysis". American Journal of Respiratory and Critical Care Medicinevol. 212, no. Supplement_1, May. 2026, pp. doi: 10.1093/ajrccm/aamag162.2000 | AstraZeneca, Boehringer Ingelheim, GSK | 0 | N/A |
| 8053 | Alexander G Mathioudakis | Manchester University NHS Foundation Trust | ICS-RECODE: Predictors of treatment REsponse to inhaled corticosteroids (ICS) in chronic obstructive pulmonary disease: randomised COntrolled trials individual participant Data re-Evaluation. | Mathioudakis, A G, Bate, S, Fortescue, R, Fullwood, C, Sperrin, M, Hurst, J R, Clarke, M, Quint, J K, Simmonds, M, Fally, M, Wang, R, Hansel, J, Miligkos, M, Manohar, S, Linnell, J, Preston, A, null, null, Woodcock, A, Stewart, L, Singh, D and Vestbo, J "B24-01 Reduced Inhaled Corticosteroid Benefit in Current Smokers With COPD: Findings From the ICS-RECODE IPD Meta-analysis". American Journal of Respiratory and Critical Care Medicinevol. 212, no. Supplement_1, May. 2026, pp. doi: 10.1093/ajrccm/aamag162.1760 | AstraZeneca, Boehringer Ingelheim, GSK | 0 | N/A |
| 8427 | Ahmad Abuhelwa | University of Sharjah | Predictors of exposure, therapeutic and adverse effects of medicines used in the treatment of multiple myeloma | Abuhelwa, Ahmad Y., Almansour, Sara A, Al-Shamsi, Humaid O., Abuhelwa, Ziad, Alqudah, Mohammad A. Y., Bustanji, Yasser, Semreen, Mohammad H, Alzoubi, Karem H, Modi, Natansh D, McKinnon, Ross A, Sorich, Michael J. and Hopkins, Ashley M ""Cardiovascular medications and treatment outcomes in multiple myeloma: insights from phase III clinical trials"". Scientific Reportsvol. 16, no. 1, Feb. 2026, pp. doi: 0.1038/s41598-026-37464-4 | Johnson & Johnson | 0 | |
| 8546 | Alice Adenis | Diabeloop | Modeling the impact of physical activity, estimated by sensors such as accelerometers and heart rate, on glycemia of Type 1 Diabetes (T1D) patients. | Heart Rate Monitoring for Early Detection of Physical Activity-Induced Hypoglycemia in Type 1 Diabetes | Jaeb | N/A | N/A |
| 8560 | Emily Fox | Stanford University | Hybrid machine learning modeling of Insulin-Glucose dynamics for T1D | Junyi Zou, Bob and Tian, Lu "Automatic and Structure-Aware Sparsification of Hybrid Neural ODEs with Application to Glucose Prediction". The Fourteenth International Conference on Learning Representations (ICLR 2026), Submission Number: 13562, 2026, doi:10.25934/PR00008560 | Jaeb | N/A | N/A |
| 8591 | John Reynolds | University of Birmingham | Patterns of skin flare in patients with systemic lupus erythematosus | Peterknecht, Elizabeth, Branco, Marco and Reynolds, John A "Sites of skin inflammation recurrence in patients with SLE: an analysis of clinical trial data". Lupus Science & Medicinevol. 13, no. 1, Feb. 2026, pp. e001916 doi: 10.1136/lupus-2025-001916 | AstraZeneca | N/A | 0 |
| 8773, 6118 | Roxana Mehran | The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai | Antithrombotic therapy in patients with atrial fibrillation after percutaneouscoronary intervention: a systematic review and individual patient data network meta-analysis Revision of 6118 | Antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation: an individual patient data network meta-analysis doi: 10.1093/eurheartj/ehag740 | Boehringer Ingelheim, Daiichi Sankyo, Inc. | 0 | |
| 8850 | Changsheng Ma | Beijing Anzhen Hospital | The impact of malnutrition on the Efficacy and Safety of empagliflozin for people with heart failure | Li, W, Zeng, R U I and Du, X I N "The effect of malnutrition on the efficacy and safety of empagliflozin: a post hoc analysis of the EMPEROR-Reduced trial". European Heart Journalvol. 46, no. Supplement_1, Nov. 2025, pp. doi:10.1093/eurheartj/ehaf784.956 | Boehringer Ingelheim | N/A | N/A |
| 8879 | Micaela Morettini | Università Poiltecnica delle Marche | Development of a decision support solution to prevent hypoglycemia during and after exercise in T1D | Piersanti, Agnese, Göbl, Christian, Burattini, Laura, Tura, Andrea and Morettini, Micaela "PREDICTING HYPOGLYCEMIA RISK IN EXERCISE: A TREE-BASED ENSEMBLE LEARNING APPROACH USING CONTINUOUS GLUCOSE MONITORING DATA". ATTD Barcelona 2026-11–14 March and ATTD-ASIA 2025 Singapore-9–11 December, SO006 / #611, Page 89S, 2026, doi: 10.1177/15209156251412178 | Jaeb | N/A | N/A |
| 8889 | Fabricio Garelli | National University of La Plata and CONICET. | Modelling short and long-term exercise effect on glucose levels from wearable devices’ signal patterns. | Links between physical activity, time-in-range and glucose predictability in people with type 1 diabetes doi: 10.1177/03913988261435494 | Jaeb | N/A | 0 |
| 8889 | Fabricio Garelli | National University of La Plata and CONICET. | Modelling short and long-term exercise effect on glucose levels from wearable devices’ signal patterns. | Artificial Neural Networks For Blood Glucose Prediction During And After Physical Exercise doi: 10.1177/15209156251412178 | Jaeb | N/A | N/A |
| 8944 | Wesley Kerr | University of Pittsburgh | Evaluation of Time to Event endpoints in randomized controlled trials of multiple antiseizure medications for uncontrolled epilepsy | Kerr, Wesley T., Reddy, Advith S., Kok, Neo, McFarlane, Katherine N., Biju, Lavanya and French, Jacqueline A. "Patterns of seizure frequency reduction in clinical trial participants with lower baseline seizure frequency". Epilepsiavol. , no. , Mar. 2026, pp. doi: 0.1002/epi.70189 | GSK, Johnson & Johnson, UCB | 0 | |
| 8957 | Dean Bodenham | Imperial College London | Two-sample testing for clinical trials data with missing values | Rank-based hypothesis testing in the presence of missing data Publication link | Bayer | N/A | N/A |
| 9018 | Alessio Cortellini | Department of Surgery and Cancer, Imperial College London (UK) | Differential effect of systemic antibiotics and proton pump inhibitors on clinical outcomes from immunotherapy or placebo as sequential therapy in patients with locally advanced, unresectable non-small cell lung cancer (stage III) who have not progressed following chemoradiation therapy: A post-hoc analysis of the PACIFIC trial. | Brunetti, Leonardo, Santo, Valentina, Pinato, David J, Citarella, Fabrizio, Orlando, Sarah, Acker, Fabian, Colella, Vittoria, Ricciuti, Biagio, Naidoo, Jarushka, Nassar, Amin, Wakelee, Heather A, Takada, Kazuki, Naqash, Abdul Rafeh, Garassino, Marina C, Greco, Carlo, Ramella, Sara, Pantano, Francesco, Tonini, Giuseppe, Vincenzi, Bruno, Arlunno, Bryan, Remon, Jordi, Parisi, Claudia, Planchard, David, Besse, Benjamin, Desilets, Antoine, Routy, Bertrand, Elkrief, Arielle, Barlesi, Fabrice, Derosa, Lisa and Cortellini, Alessio "Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial". The Lancet Oncologyvol., no., Jul. 2026, pp. doi: 10.1016/s1470-2045(26)00191-9 | AstraZeneca | 0 | |
| 9053 | Johanna Elin Gehin | Oslo University Hospital | Personalised dosing of certolizumab pegol based on serum concentration in rheumatoid arthritis | Gehin, Johanna E., Klaasen, Rolf A., Kristianslund, Eirik K., Jyssum, Ingrid, Sexton, Joseph, Warren, David J., Aletaha, Daniel, Haavardsholm, Espen A., Goll, Guro L., Syversen, Silje W. and Bolstad, Nils "The Effect of Certolizumab Pegol Dose and Dose Changes on Plasma Trough Levels: Data From a Randomized Phase III Trial". Therapeutic Drug Monitoringvol. , no. , Feb. 2026, pp. doi: 10.1097/ftd.0000000000001440 | UCB | 0 | |
| 9098 | Stéphane Oudard | Assitance Publique des Hôpitaux de Paris | External validation of a prognostic score for survival in patients with metastatic castration-resistant prostate cancer (CABASCORE) treated with Cabazitaxel | Integrated Prognostic Score in Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel – A CABASTY Post Hoc Analysis Validated by Two International Prospective Phase 3 Trials doi: 10.1016/j.euo.2026.03.022 | Sanofi | N/A | 0 |
| 9229 | Andreas Meid | Heidelberg University Hospital | MAGIC-BULLET - Model-based support of translational steps throughout drug development of antibody-drug conjugates (ADCs) in breast cancer | Meid, Andreas D., Leiva-Escobar, Ignacio, Choi, Siak-Leng and Valente, Delphine "Translational PBPK-QSP modeling platform for antibody-drug conjugates (ADC): within-target and cross-pathway validation to bridge preclinical and clinical results". vol. , no. , Feb. 2026, pp. doi: 10.64898/2026.01.30.26345218 | Roche, Daiichi Sankyo, Inc | N/A | |
| 9253 | Jiajun Yan | McMaster University | Statistical Methods for Analyzing EuroQol 5 Dimension 5 (EQ-5D) in Randomized Clinical Trials | Yan, Jiajun, Humphries, Brittany, Che, Menglu, Pullenayegum, Eleanor, Lee, Shun Fu and Xie, Feng ""An Empirical Comparison of Statistical Methods for Estimating Treatment Effects on EQ-5D in Randomized Clinical Trials". Value in Healthvol. , no. , May. 2026, pp. doi: 10.1016/j.jval.2026.04.009 | AbbVie, Biogen, Eli Lilly, Pfizer, Sanofi, Takeda | 0 | |
| 9350 | Lucy Vivash | Monash University | Evaluation of epilepsy-DOOR (Desirability of outcome ranking) as an outcome measure for therapeutic trials in drug resistant epilepsy | Vivash, Lucy, Johns, Hannah, O′Brien, Terence J. and Churilov, Leonid "The Epilepsy‐Desirability of Outcome Ranking ( doi:10.1111/ene.70531 | UCB | 0 | 0 |
| 9384 | Evyn Peters | University Of Saskatchewan | Episode duration and severity as predictors of response to desvenlafaxine and placebo in patients with major depressive disorder | Peters, Evyn M., Quadri, Adetunji, Aziz, Saba and Balbuena, Lloyd "Episode duration and severity as predictors of placebo response in major depressive disorder"". Journal of Affective Disordersvol. , no. , May. 2026, pp. 122014 doi: 10.1016/j.jad.2026.122014 | Pfizer | 0 | |
| 9410 | Abhinav Sharma | The Research Institute of the McGill University Health Centre | Proprotein convertase subtilisin/kexin type 9 (PCSK9) Inhibitors on Cardiovascular and Heart Failure Outcomes | Razaghizad, Amir, Vasques-Nóvoa, Francisco, Ni, Jiayi, Ferreira, João Pedro, Sharma, Abhinav and Huynh, Thao "PCSK9 inhibition and cardiovascular outcomes by heart failure status: a pooled analysis of SPIRE-1 and SPIRE-2". European Journal of Heart Failure, vol., no., Jul. 2026, pp., https://doi.org/10.1093/ejhf/xuag166 doi: 10.1093/ejhf/xuag166 | Pfizer | N/A | 0 |
| 9422 | James Salsbury | University of Sheffield | Developing methodology for a delayed treatment effect present in a survival trial | Salsbury, James "Assurance Methods for Adaptive Clinical Trials with a Delayed Treatment Effect"". White Rose eTheses Online UK, 2026 Publication link | Roche, Bristol Myers Squibb | N/A | N/A |
| 9478 | Lena Friberg | Uppsala University | Study on impact of scanning intervals of follow up tumor assessments on Progression Free Survival (PFS) and median PFS for Non-Small Cell Lung Cancer (NSCLC) patients treated with Atezolizumab and Docetaxel. | Man, Peng and Liu, Han "IMMORTAL TIME BIAS IN USING IMMUNE-MEDIATED ADVERSE EVENTS AS PREDICTORS OF SURVIVAL: INSIGHTS FROM A MULTISTATE MODELING APPROACH". 2026 PAGE Conference, PAGE 34 (2026) Abstr 11958, 2026 Publication link | Roche | N/A | N/A |
| 9492 | David McAllister | University of Glasgow | Understanding frailty, multimorbidity and renal failure in clinical trials: Attrition, retention and heterogeneity of treatment effects in trials for diabetes, cancer and a heterogenous set of index conditions | McChrystal, R. (2026, June 11). Attrition in randomised controlled trials: Patterns, determinants, and risk prediction using aggregate-level and participant-level trial data. Zenodo. doi: 10.5281/zenodo.20645997 | AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, Lilly, Roche, Sanofi, Takeda, UCB | N/A | N/A |
| 9734 | James Brorson | The University of Chicago | Merging data from acute stroke secondary prevention trials for analysis of stroke recurrence risks | Brorson, James, Beniwal, Simmer, Giurcanu, Mihai, Landron, Danielle, Landron, Stacie, Siegler, James E., Prabhakaran, Shyam and Johnson, Julie A. ""Creation of a Merged Harmonized Large Database of Subject-Level Data from Acute Secondary Prevention Studies in Minor Non-Cardioembolic Stroke or TIA"". Int J Cerebrovasc Dis Stroke 9: 205, 2026 doi: 10.29011/2688-8734.100205 | AstraZeneca | N/A | 0 |
| 9735 | Edouard Auclin | Institut Bergonié | Prognostic and predictive value of the lung immune prognostic index in patients with advanced small cell lung cancers treated with immune checkpoint inhibitors | Auclin, Edouard, Roulleaux Dugage, Matthieu, Gorría, Teresa, Laguna, Juan Carlos, Anguita, Diana, Montes, Angela, Rota, Michele, Ferriol-Galmes, Miquel, Vauchier, Charles, Lavaud, Pernelle, Besse, Benjamin and Mezquita, Laura "Validation of the lung immune prognostic index in extensive-stage small cell lung cancer: Post hoc analysis of the caspian and IMpower133 phase 3 trials". European Journal of Cancervol. 245, no., Sep. 2026, pp. 116955 doi: 10.1016/j.ejca.2026.116955 | AstraZeneca, Roche | 0 | |
| 9746 | María Elena Hernando Pérez | Universidad Politécnica de Madrid | PROPHECY: Preprandial Optimized Glucose Prediction with Objective Physical Exercise andCarbohydrate Estimation for Insulin Calculation in Do-it-Yourself Systems | Interpretable Multihorizon Glucose Forecasting for Assessing Nutritional Information Impact in Type 1 Diabetes Management: Model Development and Validation Study https://ai.jmir.org/2026/1/e105049 | Jaeb | N/A | 0 |
| 9809 | Emma Fröling | Universitätsmedizin Charité Berlin, clinic for psychiatry and psychotherapy | Systematic Review and Meta-Analysis of Adverse Events During Levetiracetam Therapy | Fröling, Emma, Morales Sahm, Mariel, Schmude, Marcel, Assies, Charlotte P., Wittenberg, Michael, Rosenow, Felix, Bermpohl, Felix and Riemer, Thomas G. "Reassessing the adverse event profiles of levetiracetam and brivaracetam: a systematic review and meta-analysis". Journal of Neurologyvol. 273, no. 3, Mar. 2026, pp. doi:10.1007/s00415-026-13746-9 | UCB | N/A | 0 |
| 9829 | Yuanyuan Kong | Beijing Friendship Hospital, Capital Medical University; Methodological Platform at the National Clinical Research Center for Digestive Diseases | Clinical and molecular profiles of Hepatocellular Carcinoma (HCC) treated with combination immunotherapy | Xu, Xiao-Qian, Li, Wei-Ming, Shi, Li-Chen, Wang, Hao, Li, Shun, Huang, Cheng, You, Hong, Jia, Ji-Dong, He, You-Wen and Kong, Yuan-Yuan "Beyond side effects: treatment-related adverse events are associated with improved survival outcomes in HCC patients on atezolizumab-bevacizumab therapy". BMC Cancervol., no., Jul. 2026, pp. doi: 10.1186/s12885-026-16474-5 | Roche | N/A | 0 |
| 9835 | Yuya Matsue | Juntendo University School of Medicine Graduate School of Medicine | Impact of serum hepcidin levels on the efficacy of daprodustat treatment in patients with chronic kidney disease | Fujimoto, Yudai, Matsue, Yuya, Nakade, Taisuke, Suresvar Singh, Yu, Akama, Yuka, Nakamura, Yutaka, Cao, Junzhe, Aikawa, Tadao and Minamino, Tohru "Hepcidin and Cardiovascular Events in Patients with Chronic Kidney Disease not Undergoing Dialysis: A Post-hoc Analysis of ASCEND-ND Trial". The 90th Annual Scientific Meeting of the Japanese Circulation Society (JCS2026) Abstract No. OE32-9, 2026 http://congre.co.jp/jcs2026 | GSK | N/A | N/A |
| 9835 | Yuya Matsue | Juntendo University School of Medicine Graduate School of Medicine | Impact of serum hepcidin levels on the efficacy of daprodustat treatment in patients with chronic kidney disease | Fujimoto, Yudai, Matsue, Yuya, Nakade, Taisuke, Aikawa, Tadao and Minamino, Tohru "Hepcidin and Cardiovascular Events in Chronic Kidney Disease With and Without Dialysis: Post Hoc Analysis of the ASCEND-ND and ASCEND-D Trials". Journal of the American College of Cardiology (JACC) — ACC.26 Abstracts of Original Contribution Abstract No. 26-A-12532, 2026 Publication link | GSK | N/A | N/A |
| 9863 | Yasuhiro Hagiwara | The University of Tokyo | Development of Covariate Adjustment Methods to Improve Efficiency of Randomized Clinical Trials for human immunodeficiency virus infected Patients | Hagiwara, Yasuhiro and Matsuyama, Yutaka "Statistical Efficiency of Model-Robust Direct Regression Adjustment in Randomized Clinical Trials with Binary Outcomes". Statistics in Biopharmaceutical Research, vol. , no. , Mar. 2026, pp. 1-33, doi.org/10.1080/19466315.2026.2638477 | GSK | N/A | |
| 9907 | Akihiro Hirakawa | Tokyo Medical and Dental Universit | Developing new statistical methodology harnessing nonconcurrent control data in infectious disease platform trials | Asano, Junichi, Sato, Hiroyuki, Watanabe, Shin and Hirakawa, Akihiro "Bayesian Power Prior in Platform Trials With Non‐Concurrent Control for Binary Outcomes: Development and Comparative Evaluation". Statistics in Medicinevol. 45, no. 1-2, Jan. 2026, pp. doi:10.1002/sim.70387 | Lilly, Montreal Heart Institute, NIAID | 0 | |
| 9907 | Akihiro Hirakawa | Tokyo Medical and Dental University | Developing new statistical methodology harnessing nonconcurrent control data in infectious disease platform trials | Watanabe, Shin, Shimizu, Yosuke, Sato, Hiroyuki, Uemura, Yukari and Hirakawa, Akihiro "Evolving Variants, Shifting Outcomes: Implications for Nonconcurrent Controls in Platform Trials for Pharmaceutical Statisticsvol. 25, no. 3, May. 2026, pp. doi: 10.1002/pst.70096 | NIAID, Lilly, Montreal Heart Institute | N/A | 0 |
| 9924 | Thomas Büttner | Department of Urology and Pediatric Urology, University Hospital Bonn | Evaluation of Bellmunt Risk Score as a prognostic score in metastatic-castration resistant prostate cancer | Büttner, Thomas, Klümper, Niklas, Ellinger, Jörg, Ritter, Manuel and Krausewitz, Philipp "Bellmunt Risk Score as a Prognostic Tool in Metastatic Castration-Resistant Prostate Cancer Survival". JAMA Network Open, vol. 9, no. 3, Mar. 2026, pp. e260300, doi: 10.1001/jamanetworkopen.2026.0300 | Takeda, Johnson & Johnson | 0 | |
| 9964 | João Sérgio Neves | Faculdade de Medicina da Universidade do Porto | Effects of tirzepatide versus semaglutide on cardiovascular risk in patients with type 2 diabetes | Neves, J.S., Leite, A.R., Vale, C. et al. Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial. Diabetologia (2025). Doi: 10.1007/s00125-025-06637-7 | Lilly | 1 | |
| 9966 | Luis Farhat | University of São Paulo (USP) | An evaluation of lack of early improvement and later non-response in early-onset schizophrenia: a systematic review and meta-analysis of randomized controlled trials. | Farhat, Luis C., Sampaio, E. Kim, Nunes, Deivid Deda A., Curiki, Gustavo C., Taylor, Jerome H., Bloch, Michael H. and Polanczyk, Guilherme V. "Systematic Review and Meta-Analysis: Lack of Early Improvement Predicts Inefficacy of Antipsychotics for Schizophrenia in Adolescents". Journal of the American Academy of Child & Adolescent Psychiatryvol., no., Sep. 2026, pp. doi: 10.1016/j.jaac.2026.09.002 | Eli Lilly, Johnson & Johnson, Otsuka | 0 | |
| 10032 | Shenghong Zhang | The first affiliated hospital of Sun Yat-sen University | Dynamics of Disease Activity in Monitoring Therapeutic Outcomes and Predicting Prognosis for Ulcerative Colitis | Tie, Y, Su, F, Zhang, J, Chen, M, Chen, R, Li, L and Zhang, S "P0682 One-year Dynamics of Clinical Activity During Biologics Therapy in Patients of Ulcerative Colitis"". Journal of Crohn’s and Colitisvol. 20, no. Supplement_1, Jan. 2026, pp. doi: 10.1093 | Takeda, Johnson & Johnson | N/A | N/A |
| 10032 | Shenghong Zhang | The first affiliated hospital of Sun Yat-sen University | Dynamics of Disease Activity in Monitoring Therapeutic Outcomes and Predicting Prognosis for Ulcerative Colitis | Tie, Yizhe, Su, Fengyuan, Zhang, Jianwu, Zheng, Minhui, Li, Ningyi, Zheng, Jieqi, Chen, Minhu, Chen, Rirong, Li, Li and Zhang, Shenghong "One-year dynamics of clinical activity during biologics therapy in patients of ulcerative colitis". Crohn's & Colitis 360vol., no., Jul. 2026, pp. doi: 10.1093/crocol/otag074 | Takeda, Johnson & Johnson | N/A | 0 |
| 10036 | Akihiro Hirakawa | Tokyo Medical and Dental University | Development of statistical methodology considering placebo response in randomized controlled trials targeting Alzheimer's disease | Hanazawa, Ryoichi, Sato, Hiroyuki, Suzuki, Keisuke and Hirakawa, Akihiro "Applying a statistical model-based AI method to identify prognostic factors for long-term cognitive decline in Alzheimer’s disease: Evidence from pooled placebo data of four phase III trials". International Journal of Medical Informaticsvol. 211, no. , May. 2026, pp. 106337 doi: 10.1016/j.ijmedinf.2026.106337 | Lilly | N/A | 0 |
| 10039 | Lena Friberg | Uppsala University | Evaluation of dose individualization strategies in optimizing survival and patient-reported outcomes of sunitinib treatment in patients with metastatic renal cell carcinoma | Advancing anti-cancer dose selection and individualization Publication link | Pfizer | N/A | N/A |
| 10039 | Lena Friberg | Uppsala University | Evaluation of dose individualization strategies in optimizing survival and patient-reported outcomes of sunitinib treatment in patients with metastatic renal cell carcinoma | Sex differences in sunitinib tolerability and patient-reported outcomes in metastatic renal cell carcinoma: the role of exposure and implications for precision dosing Publication link | Pfizer | N/A | N/A |
| 10046 | Matthew Galsky | Icahn School of Medicine at Mount Sinai | Exploring C-reactive protein (CRP) dynamics and resistance to immunotherapy in bladder cancer | Tran, Michelle A., Cho, Byuri Angela, Izadmehr, Sudeh, Yoo, Seong-Keun, Youssef, Dina, Anker, Jonathan F., Farkas, Adam M., Figueiredo, Igor, Lee, Karen, Ananthanarayanan, Aparna, Balan, Sreekumar, Onkar, Sayali, Banchereau, Romain, Gupta, Saurabh, Chhibber, Aparna, Wang, Li, Beaumont, Kristin G., Li, Ziao, Garcia-Barros, Monica, Bicak, Mesude, Cordon-Cardo, Carlos, Brody, Rachel, Kim-Schulze, Seunghee, Yuen, Kobe, Mariathasan, Sanjeev, Atiq, Saad O., Adeyelu, Tolulope T., Elliott, Andrew, Barata, Pedro, McKay, Rana R., Gnjatic, Sacha, Gonzalez-Kozlova, Edgar, Mehrazin, Reza, Horowitz, Amir, Sfakianos, John P., Chowell, Diego, Galsky, Matthew D. and Bhardwaj, Nina "A Tumor-Promoting Inflammatory SPP1 + Macrophage–IL6–CRP Axis Drives Immune Dysfunction in Bladder Cancer"". Cancer Discoveryvol. , no. , Apr. 2026, pp. OF1-OF26 doi: 10.1158/2159-8290.cd-25-1774 | Roche | 2 | |
| 10120 | Pablo Bonangelino | US Food and Drug Administration | A Bayesian borrowing-by-parts method integrated with propensity score stratification for borrowing adult data for pediatric patients | Das, Apu Chandra, Gwon, Yeongjin and Bonangelino, Pablo "Propensity Score-Based Borrowing-By-Parts Power Prior for Augmenting Control Arm in Clinical Trials: A Two-Stage Approach". Statistics in Biosciencesvol. , no. , Jan. 2026, pp. doi: 10.1007/s12561-026-09513-z | GSK | N/A | N/A |
| 10158 | Si-Cong Ma | The First Affiliated Hospital of Sun Yat-Sen University | Biomarker-based strategies to enhance efficacy and reduce toxicity in lung cancer immunotherapy | Wang, Si-Heng, Gao, Ning, Wang, Yu-Ze, Huang, Jiamin, Gan, Zhen, Fang, Zengli, Wang, Zekang, Chen, Rui, Feng, Xianming, Pan, Baixu, Tan, Jinghong, Cai, Junchao, Li, Mengfeng, Yang, Weixiong, Cheng, Chao and Ma, Si-Cong "Organ-metastatic landscape delineates overall and site-specific immune-related adverse events of PD-L1 blockade in advanced NSCLC".npj Precision Oncologyvol. 10, no. 1, Mar. 2026, pp. doi: 10.1038/s41698-026-01375-4 | Roche | 0 | |
| 10450 | Sam Royston | Replica Health | Merging Big Datasets for Training Blood Glucose Prediction Models | Wolff, Miriam K., Royston, Sam, Fougner, Anders L., Schaathun, Hans Georg, Steinert, Martin and Volden, Rune "A perspective on harmonizing diabetes management datasets". Data in Briefvol. 59, no. , Apr. 2025, pp. 111399 doi: 10.1016/j.dib.2025.111399 | JAEB | N/A | 2 |
| 10499 | Stefan Koudstaal | Erasmus Medical Center Rotterdam, NL | Personalized Lifetime Prediction of Survival and Treatment Benefit in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: the LIFE-Preserved Model | Reitsma, Tessa H, Savarese, Gianluigi, Kuźma, Łukasz, Deo, Salil V, Pennells, Lisa, Hageman, Steven H J, Holtrop, Joris, Benson, Lina, Conrad, Nathalie, Lund, Lars H, Kurasz, Anna, Kaptoge, Stephen, Keene, Spencer J, Chilala, Chimweta, Pitt, Matilda, Fletcher, Robert A, Khunti, Kamlesh, Piepoli, Massimo, Rossello, Xavier, Lees, Jennifer S, Kavousi, Maryam, McEvoy, John William, Wood, Angela M, de Boer, Rudolf A, Andersson, Charlotte, Visseren, Frank L J, Koudstaal, Stefan, Di Angelantonio, Emanuele, Dorresteijn, Jannick A N, null, null, Angelantonio, Emanuele, Abreu, Ana, Visseren, Frank, Kavousi, Maryam, William McEvoy, John and Wood, Angela "Risk prediction in patients with heart failure with preserved ejection fraction: the LIFE-Preserved model"". European Heart Journalvol. , no. , Mar. 2026, pp. doi: 10.1093/eurheartj/ehag182 | Boehringer Ingelheim | 2 | |
| 10540 | Alexander Drilon | Memorial Sloan Kettering Cancer Center (MSKCC) | Do patients with lung cancers positive for a RET gene alteration benefit from the addition of immunotherapy to chemotherapy? | Brief Report: First-line Chemoimmunotherapy and Chemotherapy Outcomes in Patients with RET Fusion-Positive Lung Cancer in LIBRETTO-431 - Journal of Thoracic Oncology doi: 10.1016/j.jtho.2026.104086 | Lilly | 0 | |
| 10783 | Kathryn Connelly | Monash University School of Clinical Sciences | Can a core set of disease activity domains define response in systemic lupus erythematosus clinical trials? An analysis of two Phase 3 randomised controlled trials of belimumab | Lin, Angela, Kandane-Rathnayake, Rangi, Morand, Eric F and Connelly, Kathryn "Can disease activity and treatment responses be captured by a core set of domains in SLE clinical trials? An analysis of phase III belimumab trial data". Lupus Science & Medicinevol. 13, no. 1, Jan. 2026, pp. e001928 doi: 10.1136/lupus-2025-001928 | GSK | 0 | 0 |
| 10832 | Jay Park | Core Clinical Sciences | Assessing the Potential Effect of a New Diabetes Treatment in Canadian Populations | Metcalfe, Rebecca K., Yan, Yichen, Alam, Shomoita, Dyrkton, Nathaniel, Wilbur, Jayson D., Abdul-Karim, Rasha and Park, Jay J.H. "Evaluation of the Clinical Effectiveness and Cost-Effectiveness of Tirzepatide for Type 2 Diabetes in Canada Using Bayesian Transportability Analysis". Value in Health Regional Issuesvol., no., Jul. 2026, pp. 101666 doi: 10.1016/j.vhri.2026.101666 | Eli Lilly | 0 | 0 |
| 10842 | Youqi Yang | University of Michigan | Estimating the Effect of Tirzepatide on Body Weight in Specific Subgroups: A Secondary Analysis Across Trials | Yang, Youqi, Dempsey, Walter and Mukherjee, Bhramar "Data Integration for Estimating Subgroup-Specific Conditional Average Treatment Effects (CATEs) Using Coarsened External Information in Randomized Trials". arXiv 2026 doi: 10.48550/arXiv.2604.20667 | Lilly | N/A | N/A |
| 10960 | Yin Bun Cheung | Duke-NUS Medical School, Centre for Quantitative Medicine | Extend previously approved access at CSDR (Research Proposal 12163): Novel approaches to the modelling of protective efficacy, immunity and infectious disease incidence: Malaria vaccination | Zhao, Ziwei, Milligan, Paul and Cheung, Yin Bun "Modeling time-varying efficacy of RTS,S/AS01 malaria vaccine across trial settings". npj Vaccinesvol., no., Jul. 2026, pp. doi: 10.1038/s41541-026-01519-4 | GSK | 0 | 0 |
| 11010 | João Pedro Ferreira | Faculty of Medicine of Porto University | Serum magnesium and the effect of empagliflozin in heart failure | Ferreira, João Pedro, Zannad, Faiez, Butler, Javed, Filippatos, Gerasimos, Vasques-Nóvoa, Francisco, Marques, Pedro, Neves, João Sérgio, Anker, Stefan D and Packer, Milton "Genitourinary tract infections and SGLT2 inhibitors in heart failure: an EMPEROR-Pooled analysis". European Journal of Heart Failurevol. , no. , Feb. 2026, pp. doi:10.1093/ejhf/xuag054 | Boehringer Ingelheim | N/A | 0 |
| 11010 | João Pedro Ferreira | Faculty of Medicine of Porto University | Serum magnesium and the effect of empagliflozin in heart failure | Marques, Pedro, Vasques-Nóvoa, Francisco, Pintalhão, Mariana, Bergantim, Rui, Mendonça, Luís, Neves, João Sérgio, Friões, Fernando, Sharma, Abhinav, Filipatos, Gerassimos, Butler, Javed, Anker, Stefan, Zannad, Faiez, Packer, Milton and Ferreira, João Pedro "Polycythemia, SGLT2 inhibitors, and associated outcomes across the cardio-kidney-metabolic spectrum: a pooled analysis of randomized trials". European Journal of Internal Medicinevol. , no. , Jun. 2026, pp. 106989 doi: 10.1016/j.ejim.2026.106989 | Boehringer Ingelheim, Johnson & Johnson | N/A | 0 |
| 11010 | João Pedro Ferreira | Faculty of Medicine of Porto University | Serum magnesium and the effect of empagliflozin in heart failure | Ferreira, João Pedro, Zannad, Faiez, Filippatos, Gerasimos, Marques, Pedro, Vasques-Nóvoa, Francisco, Neves, João Sérgio, Mendonça, Luis, Butler, Javed, Anker, Stefan D. and Packer, Milton "Impact of empagliflozin on serum calcium and phosphate in heart failure". Journal of Cardiac Failurevol., no., Aug. 2026, pp. doi: 10.1016/j.cardfail.2026.07.026 | Boehringer Ingelheim | N/A | 0 |
| 11162 | Morgan Grams | NYU Grossman School of Medicine | Global Study on How Chronic Kidney Disease Affects Cardiovascular Disease Risk | Neuen, Brendon L., Major, Rupert W., Grams, Morgan E., Sang, Yingying, Coresh, Josef, Ballew, Shoshana H., Surapaneni, Aditya, de Pinho, Natalia Alencar, Arnlov, Johan, Arnott, Clare, Bell, Samira, Berry, Jarett, Brenner, Hermann, Ciemins, Elizabeth, Chang, Alexander R., Cushman, Mary, de Lemos, James A., Diaz-Tocados, Juan Miguel, Farjat, Alfredo E., Fletcher, Robert A., Gansevoort, Ron T., Heerspink, Hiddo J. L., Herrington, William G., Hong, Chuan, Horwitz, Edward J., Hwang, Shih-Jen, Jassal, Simerjot K., Kalra, Philip A., Katz, Ronit, Khan, Sadiya S., Kovesdy, Csaba P., Kronenberg, Florian, Lees, Jennifer S., Lloyd-Jones, Donald M., Mill, Jose Geraldo, Naimark, David M. J., Ndumele, Chiadi, Polkinghorne, Kevan R., Psaty, Bruce M., Schloemer, Patrick, Shlipak, Michael, Shrestha, Prabin, Song, Zean, Staplin, Natalie, Steubl, Dominik, Vart, Priya, Visseren, Frank L. J., Woodward, Mark, Yamagishi, Kazumasa, Young, Bessie A., Sabanayagam, Charumathi and Valdivielso, Jose M. "Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals"". Nature Medicinevol. , no. , May. 2026, pp. doi: 10.1038/s41591-026-04437-z | Boehringer Ingelheim | 0 | |
| 11328 | Katie Bechman | King's College London | Effects of obesity on treatment response to Janus kinase inhibitors (JAKi) in rheumatoid arthritis | Bechman, Katie, Russell, Mark D, Biddle, Kathryn, Gibson, Mark, Brown, Jeremy, Rutherford, Andrew I, Nikiphorou, Elena, Perucha, Esperanza, Cope, Andrew P, Norton, Sam and Galloway, James "Impact of BMI on response to Janus kinase inhibitors in rheumatoid arthritis: an individual patient data meta-analysis of randomised controlled trials". The Lancet Rheumatologyvol. 8, no. 9, Sep. 2026, pp. e691-e703 doi: 10.1016/s2665-9913(26)00151-7 | AbbVie, Eli Lilly, Pfizer | 0 | |
| 11350 | Neeraj Narula | Hamilton Health Sciences | Modified Multiplier Simple Endoscopic Score for Crohn's Disease (MM-SES-CD) Thresholds as Predictors of Delayed Clinical Response to Upadacitinib in Patients with Crohn’s Disease | Wong, Emily C.L., Dulai, Parambir S., Marshall, John K., Jairath, Vipul, Reinisch, Walter and Narula, Neeraj "Week 12 Reduction in Modified Multiplier of the Simple Endoscopic Score for Crohn’s Disease is Predictive of Delayed Response to Upadacitinib in Crohn’s Disease". Clinical Gastroenterology and Hepatologyvol. , no. , Dec. 2025, pp. doi: 10.1016/j.cgh.2025.12.020 | AbbVie | 0 | |
| 11640 | Pierpaolo Pellicori | University of Glasgow | Effect of Empagliflozin on Neutrophil and Lymphocyte Counts, and their Ratio, in Patients with Heart Failure: the EMPEROR Program | Neutrophil-to-Lymphocyte Ratio in Patients With Heart Failure: Findings From The EMPEROR Program doi: 10.1093/eschf/xvag243 | Boehringer Ingelheim | 0 | 0 |
| 11690 | Soumyajit Roy | University Hospitals Cleveland Medical Center | Training and Validation of PSA and Pain as Biomarkers and Causal Mediators in Metastatic Hormone Sensitive Prostate Cancer | Roy, Soumyajit, Lichtman-Mikol, Samuel, Armstrong, Andrew J., Agarwal, Neeraj, Garcia, Jorge A., Jia, Angela Y., McKay, Rana R., Brown, Jason Robert, Basourakos, Spyridon P., Sheng, Iris Yeong- Fung, Kishan, Amar Upadhyaya, Barata, Pedro C., Shoag, Jonathan Evan, Zaorsky, Nicholas G., Morgan, Scott C., Wallis, Christopher J.D., Saad, Fred, Shore, Neal D., Sun, Yilun and Spratt, Daniel Eidelberg "Independent validation of a model to predict early favorable PSA response (NADIR model) in enzalutamide-treated patients of the ARCHES trial.". Journal of Clinical Oncologyvol. 44, no. 16_suppl, Jun. 2026, pp. 5082-5082 doi: 10.1200/jco.2026.44.16_suppl.5082 | Astellas, Bayer, Johnson & Johnson | 0 | N/A |
| 11916 | Kate Sutherland | Walter and Eliza Hall Institute of Medical Research | Investigating biomarkers of response to immunotherapy in small cell lung cancer | Ng, Jin, You, Yue, Zhang, Tina Z., Hess, Jonas B., Best, Sarah A., Caneborg, Alex, Schmiel, Marcel, Diepstraten, Sarah T., Spelman, Tim, Gray, Joshua I., Godfrey, Dale I., Wu, Yin, Tothill, Richard W., Anttila, Casey J.A., Baldwin, Tracey M., Naik, Shalin H., Amann-Zalcenstein, Daniela, Kersbergen, Ariena J., Leong, Tracy L., George, Julie, Ritchie, Matthew E., Gherardin, Nicholas A., Koay, Hui-Fern, Hickey, Peter F., Steinfort, Daniel and Sutherland, Kate D. "γδ T cells modulate anti-tumor immunity in small cell lung cancer". Cancer Cellvol., no., Sep. 2026, pp. doi: 10.1016/j.ccell.2026.08.015 | AstraZeneca | 0 |
Center for Global Research Data